Position in CYTK
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$588,150
-$8,627 QoQ
Shares Held
6,904
-47.3% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#294
of 477 holders
Holding Since
Jun 2020
8 quarters on record
Voting authority
Sole 57%
Shared 0%
None 43%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TRUIST FINANCIAL CORP holds $119,348,952 across 50 Biotechnology names. CYTK ranks #29 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
106,967 | $53,133,716 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
38,731 | $24,150,326 | |
| 3 | ARGX |
Argenx SE
|
3,790 | $3,516,247 | |
| 4 | EXEL |
Exelixis, Inc.
|
63,541 | $3,457,265 | |
| 5 | URGN |
UroGen Pharma Ltd.
|
72,286 | $2,660,124 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
10,121 | $2,438,856 | |
| 7 | VCEL |
Vericel Corp
|
51,315 | $2,283,003 | |
| 8 | RPRX |
Royalty Pharma plc
|
29,890 | $1,675,931 |
All Filings in CYTK
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $588,150 | 6,904 | Shares | Defined | 2026-07-28 | |
| 2021-12-31 | $596,777 | 13,093 | Shares | Defined | 2022-02-14 | |
| 2021-09-30 | $469,408 | 13,134 | Shares | Defined | 2021-11-05 | |
| 2021-06-30 | $260,296 | 13,153 | Shares | Defined | 2021-08-16 | |
| 2021-03-31 | $306,286 | 13,168 | Shares | Defined | 2021-05-17 | |
| 2020-12-31 | $256,424 | 12,340 | Shares | Defined | 2021-11-19 | |
| 2020-09-30 | $263,870 | 12,188 | Shares | Defined | 2021-11-05 | |
| 2020-06-30 | $217,951 | 9,247 | Shares | Defined | 2021-11-16 | |
| No filing history on record for this holder in this stock. | ||||||